Phase II/III randomized trial of TCH346 in patients with ALS

  • R. Miller
  • , W. Bradley
  • , M. Cudkowicz
  • , J. Hubble
  • , V. Meininger
  • , H. Mitsumoto
  • , D. Moore
  • , H. Pohlmann
  • , D. Sauer
  • , V. Silani
  • , M. Strong
  • , M. Swash
  • , E. Vernotica
  • , Neil Cashman
  • , Andrew Eisen
  • , Charles Krieger
  • , Angela Genge
  • , Sanjay Kalra
  • , John Turnbull
  • , Lucette Lacomblez
    • William Camu, Alain Destee, Albert Christian Ludolph, Reinhard Dengler, Thomas Meyer, Adriano Chio, L. H. Van Den Berg, M. De Visser, Francois Vingerhoets, Orla Hardiman, N. Leigh, Jeremy Shefner, William David, Michael Graves, Terry Heiman-Patterson, Hans Neville, Jeffrey Rosenfeld, Mark Bromberg, Andrea Corse, Andrew Waclawik, Erik Pioro, Robert Sufit, Stanley Appel, Robert Pascuzzi, John Kissel, Carlayne Jackson, Richard Barohn

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II/III randomized trial of TCH346 in patients with ALS'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience